Envision Pharma Group appoints Head of Envision Value & Access

Envision Pharma Group is pleased to announce the appointment of Mel Formica as its Head of Envision Value & Access.

Envision Pharma Group appoints Head of Envision Value & Access

Oct 03, 2022
Envision Pharma Group appoints Head of Envision Value & Access Image

Mel is a highly respected international life science leader with proven P&L and operational leadership experience, as well as private equity advisory expertise. As an innovator in developing distinctive market entry and commercial strategies that combine customer insight, vision, and creativity, Mel’s work is focused on the forefront of transformations in disruptive technologies, patient-level data, and improved quality of care.

Joining and strengthening an experienced Executive Leadership Team (ELT) at Envision, Mel will drive the growth and expansion of the Value & Access group, pursue service solution innovations, and spearhead the introduction of digital and data analytical capabilities that create impact and deliver value to life science clients.

Meg Heim, Envision’s Chief Executive Officer, said of Mel’s appointment, “Mel’s skillset and experience in industry and consulting aligns closely with our group strategy. His appointment comes at a point where our performance is accelerating and where we continue to drive forward, at pace, in delivering for clients in key strategic areas such as data and digital transformation. I am excited about the innovation, impact, and value he will bring to the talented teams here at Envision, and to our life science clients.”

Mel added, “I am thrilled to be joining Envision at such an exciting time for the group. With a new CEO, ambitions for significant growth, and a drive for greater value and access service and technology integrations, I can’t think of a better time to be joining, supporting the ELT, and advancing the group strategy.”

Close

Envision the Patient welcomes Amanda Boughey to the team as Global Patient Partnership Director

Envision Pharma Group Wins Gold Events & Exhibitions Award at PM Society Awards in Collaboration With Mundipharma

Envision’s innovative engagement experience with interactive projection mapping for Mundipharma (pictured) captured the attention of the judges

Envision Upsizes Office in Tokyo

Envision the Patient welcomes Amanda Boughey to the team as Global Patient Partnership Director

Jun 12, 2019
Envision the Patient welcomes Amanda Boughey to the team as Global Patient Partnership Director Image

Envision Pharma Group is announcing the expansion of its award-winning Envision the Patient team with the appointment of Amanda Boughey as Global Patient Partnership Director from her previous role with Cancer Research UK.

Harnessing over 17 years’ experience in patient-centred healthcare strategy and communications, Amanda will help increase the range of services already offered by Envision in medical affairs and patient partnership – under the leadership of Professor Karen Woolley.

Amanda joins Envision from Cancer Research UK, a world-renowned research and campaign organisation, where she lead multi-stakeholder initiatives comprising clinicians, patients and policy makers – to drive activities focused on the early diagnosis of cancer. Prior to this role, Amanda worked within healthcare agencies delivering global integrated communication programmes in a range of therapy areas, and specialised in patient engagement, behaviour change projects and communications.

In welcoming Amanda, Professor Woolley said, “I believe we’ve passed the tipping point with patient involvement in the pharma industry and are beginning to deeply understand how it will influence and transform the way we work. Evidence of this transformation can already be seen across medical publications, scientific congresses and indeed Medical Affairs teams as they build resources dedicated to patient engagement.

“Our own Envision team recently won the ‘Best Practice’ Award at ISMPP for our research on plain language summaries and the toolkit we co-created with patients, industry, publishers and plain language specialists. It really is an exciting time to be working in this area and I am delighted that Amanda is joining our team to help clients achieve more, bringing years of experience and skills working with pharma, clinicians and patient advocacy groups”.

Amanda added, “Envision has a fascinating, evidence-based approach and access to a broad group of stakeholders within healthcare, so I’m looking forward to working with all of them to amplify the patient voice and ensure patients have access to the very best in scientific research and understanding.”

For further information on Envision the Patient services, please contact: info@envisionthepatient.com

Close

Envision Pharma Group Wins Gold Events & Exhibitions Award at PM Society Awards in Collaboration With Mundipharma

Feb 04, 2019
Envision Pharma Group Wins Gold Events & Exhibitions Award at PM Society Awards in Collaboration With Mundipharma Image

Envision Pharma Group was awarded for outstanding creativity, impact and innovation at the 33rd annual PM Society Awards held at the Grosvenor House in London on February 1, 2019.

The PM Society Awards recognise creativity, impact and innovation across pharmaceutical and healthcare advertising and communications. Their target categories are judged by online healthcare professional surveys, and others by panels drawn from creative agencies and industry.

In addition to winning the Events & Exhibitions Award Gold, Envision also secured a bronze award in the Innovation category.

Global Innovation Director at Envision Vonig Watson said, “Envision Pharma Group are extremely proud to have won both Gold and Bronze at the PM Society Awards for our work in collaboration with Mundipharma.

“Reaching audiences in innovative and engaging ways to offer those individuals real value via tailored experiences has been a real success story for EPG. Gone are the days of forcing content on audiences with the hope of maximum impact and lasting message retention. We understand that audiences choose when and how they engage with content, and in creating unique experiences, we are able to achieve the desired reach and impact. This helps our clients effectively communicate their messages to the right audiences at the right time.

“These awards reflect Envision Pharma Group’s passion in delivering scientific and medical communications effectively. Being selected for this award by an acclaimed judging panel of our peers is recognition of all the hard work that went into achieving this. A huge thank you to the creative team, and to our partners Mundipharma for having the faith and vision to help us bring this to life.”

Click here to access video highlights of this experience, and see our award-winning creative solutions.


Close

Envision Upsizes Office in Tokyo

Jan 30, 2019
Envision Upsizes Office in Tokyo Image

Envision is delighted to announce that our ProScribe KK team have moved to new and larger offices in Kojimachi Tokyo, close to the Imperial Palace.

2019 looks set to be an exciting year for ProScribe KK, with its growth in Japan running parallel with the global growth of Envision Pharma Group.

Katsuhisa Arai, General Manager, commented, “The rise of Medical Affairs in Japan has certainly increased client demand for our scientific and technology solutions. With our new offices, we can continue to attract talented and experienced staff to our ProScribe KK team. This will allow us to meet our clients’ increasing needs for ethical and effective solutions.

“Our commitment to our clients is consistent with our company values, including the values of ‘working together’ (relationship 縁) and ‘creating value’ (perform 演). The ProScribe KK team remains most grateful for the trusted and respectful relationships we have with our clients in Japan.”

Close

Envision adds iEnvision Datavision for Medical Publication Management to suite of Medical Affairs Solutions

2019 European Meeting of ISMPP: iEnvision and Patient Partnership

Happy Holidays From Envision Pharma Group

Envision adds iEnvision Datavision for Medical Publication Management to suite of Medical Affairs Solutions

Jan 21, 2019
Envision adds iEnvision Datavision for Medical Publication Management to suite of Medical Affairs Solutions Image

Envision Pharma Group is pleased to announce the addition of iEnvision Datavision® to the suite of medical affairs support solutions available on the iEnvisionTM platform.

Datavision was originally launched 15 years ago, and has become the industry standard system for global publication management, in use by 19 of the current top 20 pharmaceutical companies.

iEnvision Datavision builds on this industry-wide experience as the new publication management system of choice, with both updated functionality and the wider benefits of the iEnvision platform.

iEnvision Datavision supports industry standards in guideline-compliant medical publication plan management, with functionality supporting enhanced planning, publication development and plan monitoring tasks – improving both strategic alignment and publication management efficiency.

iEnvision Datavision includes industry standard workflows for various publication types, which are adjustable to align with company SOPs. Other iEnvision Datavision features include the most comprehensive peer-reviewed journal and medical congress database available in the industry, together with a new built-in debarment-checking tool.

Envision Technology Solutions’ Platform Lead Russell Traynor said, “iEnvision Datavision, builds on our years of experience with Datavision and medical publications, and is designed to support GPP3 and ICMJE compliant publication planning and development.”

Like other iEnvision solutions, iEnvision Datavision is entirely web-delivered and cloud-based – requiring no installation – and allows platform-level connectivity with both other iEnvision medical affairs solutions and third party systems. The user-friendly and consistent iEnvision user interface includes in-system document editing, reviews and approvals for in-development publications – and presents information from Altmetric and Scopus for published materials.

iEnvision Datavision joins the other available iEnvision solutions supporting content management, internal and externally sponsored research projects, medical education grants, corporate grant making and medical information provision – in a fully connected suite of solutions supporting medical affairs and allied functions.

Close

2019 European Meeting of ISMPP: iEnvision and Patient Partnership

Jan 17, 2019
2019 European Meeting of ISMPP: iEnvision and Patient Partnership Image

Envision Pharma Group will be in London for this year’s European Meeting of ISMPP and will be highlighting iEnvision Datavision – a core Solution within our suite of medical affairs support, and the evolution of patient partnership within our medical communications and publications focus.

Held between 22-23 January, the theme for this year is ‘Scientific Communications in a Fast-Paced World: Fighting Fit for the Future’, and sees us hosting roundtable events on patient partnership, plain language summaries and meaningful metrics.

The meeting provides an ideal opportunity for delegates to catch up with all the very latest developments on the iEnvision platform, and to view our co-authored poster with industry and patient partners: ‘Developing plain language summaries of scientific congress abstracts – with patients, for patients: a feasibility study’.

Do stop by our booth to speak to us and get involved in the activities. To find out more, view the ISMPP schedule.

Close

Happy Holidays From Envision Pharma Group

Dec 20, 2018
Happy Holidays From Envision Pharma Group Image

From everyone at Envision Pharma Group we wish you a wonderful Holiday Season, and a Happy New Year!

Close

Envision Pharma Group Collaborates With the Medical Affairs Professional Society (MAPS)

Envision Pharma Group and Ectodermal Dysplasia Society Develop Patient Initiative Booklet Aimed at Children About Genetic Disorder

A White Paper - The Value of Medical Affairs

Envision Pharma Group Collaborates With the Medical Affairs Professional Society (MAPS)

Oct 25, 2018
Envision Pharma Group Collaborates With the Medical Affairs Professional Society (MAPS) Image

Each year, Medical Affairs (MA) teams demonstrate leadership and value through the annual strategic planning process that aligns all multifunctional MA competencies on common objectives. These objectives support the product and organization, and depend on a focused and cohesive medical strategy. A product or organization’s strategy is the foundation for the year ahead and will serve as guidance for overcoming challenges, taking advantages of opportunities, and filling any scientific or clinical gaps.

Envision team members, Joe Kohles and Leah Williams, were afforded the opportunity to collaborate with industry-leading MA professionals, to create the first in a series of standards and guidance documents for MAPS focused on strategic MA planning for a product, the Medical Affairs Strategic Planning Guide and Template. Included in the template and guide are guidance and recommendations on key components of developing a medical plan – including the situational analysis, medical strategy, tactical/operational planning, and medical plan summary.

To access the Medical Affairs Strategic Planning Guide and Template, please visit the MAPS website via this link.

Close

Envision Pharma Group and Ectodermal Dysplasia Society Develop Patient Initiative Booklet Aimed at Children About Genetic Disorder

Oct 24, 2018
Envision Pharma Group and Ectodermal Dysplasia Society Develop Patient Initiative Booklet Aimed at Children About Genetic Disorder Image

Envision Pharma Group has collaborated with the Ectodermal Dysplasia Society in order to develop a patient information booklet aimed at children that raises awareness and support for the disorder.

“Everybody’s different: An introduction to Ectodermal Dysplasia” has been designed for children aged 4+, with and without ED, and allows parents and schools to explain the condition in child-friendly terms. It facilitates empathy and gives children the ideas and motivation to then help their peers.

Ectodermal Dysplasias are a group of genetic disorders affecting the development or function of the teeth, hair, nails and sweat glands. As the condition often has obvious physical symptoms, and children need extra support, they can be subject to bullying or exclusion by their peers.

Envision utilised its services in patient-focused content strategy, copywriting, illustration and graphic design to work closely with the charity to co-create the booklets that help children explore visible and invisible differences – as well as thinking about the emotional impact of those variances.

As a result of this collaboration, Envision is now among finalists in the Global Healthcare and Pharma Advertising Awards for the Ectodermal Dysplasia booklet, under a “Health Awareness and Advocacy” category.

Creative Strategy and Content Director Sarah Ings from Envision added, “We have created something that will provide many discussion points for children and their peers. The key to its development was a close relationship and co-creation process with those experienced in the condition. Co-creation is a fundamental part of the development of patient materials, and we are honoured to have been able to work with the charity in this way.”

The Ectodermal Dysplasia Society work together with people who have ED, their families, researchers, health and other professionals to develop and share expertise, increase awareness and understanding, and assist with the day-to-day management of ED.

ED Society CEO Diana Perry commented, “My first approach to Envision was to have an age appropriate children’s leaflet produced to help children explain to their peers the genetic condition they have, but over time this evolved into this fantastic booklet. We are so grateful to Envision for their passion and dedication in creating this, which will not only help children affected by ED but all children who are a little different. It has been a huge pleasure working alongside Envision’s team on this project.”

To access a copy of the patient information material and to find out more, click here.

Close

A White Paper - The Value of Medical Affairs

Sep 19, 2018
A White Paper - The Value of Medical Affairs Image

Medical Affairs (MA) teams oversee important internal and external activities that define clinical development, stakeholder relationships, scientific communications, and education across the pharmaceutical industry. As MA becomes an increasingly more critical part of organizations, MA teams are striving to develop new and relevant metrics that ensure the effectiveness and efficiency of their teams and will, in turn, lead to the demonstration of value and communicate the importance of MA to the broader pharmaceutical organization.

This white paper, created by the Envision team in concert with industry-leading MA professionals, provides comprehensive guiding principles on how to define, measure, and communicate the value of MA to the broader organization through the annual medical planning process, with a critical focus on how to link meaningful metrics in MA to desired outcomes.

Close

September is Blood Cancer Awareness Month

Envision expands capacity out of UK Horsham office

Pharma’s Response to the Patient Voice

September is Blood Cancer Awareness Month

Sep 17, 2018
September is Blood Cancer Awareness Month Image

Blood cancer happens when there is a problem with the development of blood cells. The most common type of blood cancer is lymphoma, and the symptoms are general and often overlooked. There are 2 main types of lymphoma: Hodgkin lymphoma and non-Hodgkin lymphoma, and it is important to tell the difference between these as doctors treat them differently

Join us in our mission to raise awareness and share this infographic we have developed via your social media channels, you can use these popular hashtags:

#FightBloodCancer
#lymphoma
#endcancer

Close

Envision expands capacity out of UK Horsham office

Aug 14, 2018
Envision expands capacity out of UK Horsham office Image

Envision Pharma Group has moved into new office space in Horsham and is remodelling its original office in the town to facilitate unprecedented business growth, while offering an enhanced working environment.

Office space at St Mark’s Court in Horsham was acquired which now provides seating and facilities for an extra 73 team members. Envision's Chief People Officer Petra Battersby stated, “Envision is not just a brand, it is a culture each of us embraces. Our continued success is down to our people, we endeavour to give our teams the best environments to work within and to continue to support them along their chosen career path.”

Envision received an award in March at an event that celebrates the fastest-growing companies in Sussex – an accolade it has consistently achieved. This latest expansion shows it to be an exciting time for the business, clients and new talent in the medical affairs arena.

The company currently has 14 offices, five in the UK – Bishop’s Stortford, Horsham, London (Hammersmith), Marlow and Wilmslow; one in Serbia; six in the US – Philadelphia, PA; New York, NY; Southport, CT; Madison, NJ; Stirling, NJ and Glastonbury, CT; and two in Asia Pacific – Tokyo and Sydney.

Close

Pharma’s Response to the Patient Voice

Jul 09, 2018
Pharma’s Response to the Patient Voice Image

The power of the patient voice is increasing. Patients, enabled by technology, are becoming more and more active in their own care. The healthcare industry model is changing as a result and the pharmaceutical industry needs to respond.

We have prepared a report which looks at the reaction to date, citing information gathered from eyeforpharma in Barcelona, Envision Pharma Groups ongoing research activities in this space and our unique Patient Forum in London earlier this year. Ultimately, it asks what does the future look like for pharma and patients alike? Patient centricity – trend or truth?

Download report Close